Envista (NVST) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 19, 2026, to be held virtually, with voting rights for shareholders of record as of March 23, 2026.

• Key business items include electing eight directors, ratifying the independent auditor, approving executive compensation, and determining the frequency of future say-on-pay votes.

• The company reported FY25 revenue of $2.7B, 8.3% total sales growth, and a 13.7% adjusted EBITDA margin.

• The company operates in over 130 countries with more than 12,000 employees and a portfolio of 30+ dental brands.

Voting matters and shareholder proposals

• Shareholders will vote on electing eight director nominees for one-year terms.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.

• Advisory approval of named executive officer compensation and the frequency of future advisory votes (board recommends annual votes).

• Shareholders may submit proposals for the 2027 meeting by December 8, 2026.

Board of directors and corporate governance

• Seven of eight directors are independent; all committees are fully independent.

• Board leadership is separated between an independent Chairperson and the CEO.

• Board committees include Audit, Compensation, Nominating and Governance, and Finance, each with defined oversight roles.

• Annual board and committee self-assessments are conducted.

• No stockholder rights plan is in place; robust stock ownership requirements for directors and executives.